Psychotropic medications (antidepressants, antipsychotics, mood stabilizers, anxiolytics) frequently cause adverse oral effects most commonly xerostomia (dry mouth), but also bruxism, orofacial movement disorders, increased caries, candidiasis and mucosal changes. These manifestations impair oral function, reduce quality of life, and increase dental disease risk. This review and clinical guidance summarize evidence based strategies to prevent, identify, and manage psychotropic induced oral disorders. Key measures include proactive screening and patient education, regular dental review, targeted preventive dentistry (fluoride, salivarystimulating measures), pharmacologic treatments (topical/systemic sialogogues such as pilocarpine/cevimeline for persistent xerostomia), symptomatic therapies (saliva substitutes, sugar-free lozenges, humidification), dental appliances (occlusal splints for bruxism), and pharmacologic adjustments when appropriate (dose reduction, switching to lower-anticholinergic agents, or adding medications such as buspirone or gabapentin for drug-induced bruxism/dyskinesia under psychiatric supervision). Close liaison between psychiatrists, dentists, and primary care clinicians is essential to balance psychiatric stability with oral health. Implementing structured screening protocols and multidisciplinary pathways increases timely detection and effective management of oral complications, reduces downstream dental morbidity, and improves patient adherence to psychotropic treatment. Practical algorithms and examples from the literature are provided to help clinicians adopt these interventions in outpatient and inpatient settings.